Clinical TrialJun 25, 2026, 04:02 PM
Ascendis Pharma Presents New Achondroplasia Clinical Data
AI Summary
Ascendis Pharma A/S announced it will present new clinical data from its achondroplasia programs at ICCBH 2026. This includes Week 104 data from the pivotal ApproaCH Trial for TransCon CNP, showing improvements in lower-extremity alignment. Additionally, Week 52 radiographic and anthropometric data from the COACH Trial for combination therapy with TransCon CNP and TransCon hGH will be presented.
Key Highlights
- Ascendis Pharma to present Week 104 data from ApproaCH Trial for TransCon CNP.
- Data shows continued improvements in lower extremity alignment in achondroplasia.
- Late-breaking poster to feature Week 52 data from COACH Trial for combination therapy.
- COACH Trial data includes radiographic and anthropometric results for TransCon CNP + TransCon hGH.
- TransCon CNP (YUVIWEL) was approved by US FDA in February 2026 for achondroplasia.
- TransCon hGH (SKYTROFA) is approved for growth hormone deficiency and investigational in achondroplasia.
Price Impact
More from ASND